Disclaimer: This article is intended for research and educational purposes only. BPC-157 is not an approved drug or therapeutic agent. Nothing in this article constitutes medical advice, and this compound is not intended for human consumption or clinical use. Always consult applicable regulatory frameworks before handling research-grade compounds.
If you’ve been following peptide research news this year, you’ve probably seen the headlines: BPC-157 is no longer on the FDA’s 503A Category 2 list. For researchers, pharmacists, and those tracking the regulatory landscape of research peptides in Canada and the U.S., this development has generated significant questions — and a fair amount of misinformation.
This post cuts through the noise. We’ll explain exactly what the FDA’s 503A framework is, what Category 2 meant for BPC-157, what its removal actually signals, and what remains unchanged from a regulatory and research perspective.
What Is the FDA’s 503A Bulk Substances List?
The FDA’s 503A framework governs compounding pharmacies — licensed facilities that prepare custom formulations for patients when commercial alternatives are unavailable or unsuitable. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, certain bulk drug substances can be used by these pharmacies if they appear on an FDA-nominated list.
The list has three relevant categories:
- Category 1: Nominated substances the FDA has determined may be appropriate for compounding.
- Category 2: Substances nominated for use in compounding but for which the FDA has *insufficient data* or *concerns* — essentially a “watchlist” under active evaluation.
- Category 3: Substances the FDA has determined are *not* appropriate for compounding.
BPC-157 (Body Protection Compound-157) was previously listed under Category 2, meaning it was flagged for closer FDA scrutiny due to unresolved safety or efficacy questions.
What Changed in 2026: BPC-157 Drops Off Category 2
The FDA’s updated 503A bulk substances list, published May 14, 2026, no longer lists BPC-157 under Category 2. As of that update, Category 2 contains only six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine for intrauterine administration.
BPC-157 is absent.
This has led some sources — particularly vendor blogs and community forums — to interpret the omission as a regulatory “green light.” That interpretation is incorrect, and understanding why requires reading the FDA’s framework carefully.
What Removal From Category 2 Does NOT Mean
Removal from the Category 2 watchlist does not mean any of the following:
- BPC-157 is FDA-approved. Approval requires a formal New Drug Application (NDA) or Biologics License Application (BLA) process — a process BPC-157 has not undergone.
- BPC-157 is now safe for human use. The FDA’s 503A categories relate to compounding eligibility, not a clinical safety endorsement.
- Compounding pharmacies can now freely prepare BPC-157. A substance not on *any* 503A list occupies a grey zone — it’s not explicitly approved for compounding, nor has it been moved to Category 3 (prohibited). This creates legal ambiguity, not a permission slip.
- BPC-157 is available for human clinical use in Canada. Health Canada has not issued a Drug Identification Number (DIN) or Natural Product Number (NPN) for BPC-157 in any form. It remains a research compound in Canada as well.
What the Evidence Base Actually Shows
BPC-157 is a synthetic pentadecapeptide — a sequence of 15 amino acids — originally derived from a protective protein found in gastric juice. It has been the subject of preclinical research since the 1990s, primarily in rodent models.
The research landscape, organized by tissue type:
| Tissue / System | Evidence Level | Key Findings (Preclinical) |
|—|—|—|
| Tendon / Ligament | Moderate (animal) | Accelerated healing in rat Achilles tendon models |
| Gastrointestinal | Moderate (animal) | Ulcer healing, gut mucosal protection in rodent models |
| Skeletal Muscle | Low–Moderate (animal) | Muscle crush and laceration recovery in rats |
| Nerve / CNS | Low (animal) | Preliminary data on nerve regrowth; stroke models |
| Bone | Low (animal) | Fracture healing observations in a small number of studies |
| Human Clinical Trials | None published | No completed Phase 1, 2, or 3 human trials as of May 2026 |
The critical gap: no human clinical trial data exists. Every claim about BPC-157’s “benefits” in humans is extrapolated from animal models. This is a standard limitation in early-stage peptide research, but it’s one that many vendor-facing content pieces obscure or omit.
BPC-157 and the Canadian Research Context
For Canadian researchers and institutions, the regulatory picture is somewhat different from the U.S. framework. Canada’s Food and Drugs Act distinguishes between approved drugs (with a DIN) and research compounds used within licensed research settings.
BPC-157 is available as a research reagent from licensed Canadian suppliers — including WebberScience — strictly for laboratory and research applications. It is not approved for human therapeutic use and does not hold a DIN. Importation and use must comply with applicable Health Canada guidelines.
This matters for researchers sourcing BPC-157 in 2026: supply chains, certificate of analysis (CoA) standards, and purity specifications remain the primary quality benchmarks in the absence of clinical approval, and selecting a reputable Canadian supplier with documented third-party testing is non-negotiable.
Why This Regulatory Moment Matters for Peptide Research
The movement of BPC-157 off the FDA’s Category 2 list is part of a broader 2026 trend: increased FDA scrutiny on the entire peptide compounding space. This year has seen:
- April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, with public comment due June 29, 2026.
- April 1, 2026: FDA clarified enforcement policy around compounded GLP-1s as national shortages stabilize.
- May 14, 2026: Updated 503A list narrows Category 2 to just six substances, leaving dozens of previously-listed peptides — including TB-500, KPV, MOTS-c, Semax, and Epitalon — off all categories.
The FDA appears to be tightening the regulatory perimeter rather than relaxing it. For researchers and institutions working with these compounds, staying current on regulatory updates is now a continuous requirement, not a periodic check-in.
Frequently Asked Questions
Q: Is BPC-157 legal to purchase in Canada for research purposes?
BPC-157 can be sourced as a research reagent in Canada through licensed suppliers. It is not approved for human therapeutic use and does not hold a Drug Identification Number (DIN). Researchers should verify applicable Health Canada guidelines for their institution and use case.
Q: Does removal from FDA Category 2 mean BPC-157 is safe for humans?
No. FDA 503A category classifications relate to compounding pharmacy eligibility frameworks, not clinical safety determinations. BPC-157 has no completed human clinical trials and no FDA drug approval.
Q: What is the difference between FDA Category 2 and Category 3 for peptides?
Category 2 contains substances under active FDA evaluation where data is insufficient or concerns exist. Category 3 contains substances the FDA has determined are inappropriate for compounding. BPC-157 is now in neither category — it was removed from Category 2 without being moved to Category 3, leaving its compounding status ambiguous rather than resolved.
Q: Are there any completed human trials on BPC-157?
As of May 2026, no completed Phase 1, 2, or 3 human clinical trials on BPC-157 have been published. All available evidence is from preclinical (animal) studies.
Q: What should researchers look for when sourcing BPC-157?
Third-party tested purity (HPLC and mass spectrometry), a complete Certificate of Analysis (CoA), documented sequence confirmation, and supply from a licensed Canadian research reagent supplier. These standards matter more — not less — in the absence of a regulatory approval framework.
Conclusion
The removal of BPC-157 from the FDA’s 503A Category 2 list in May 2026 is a regulatory event worth understanding clearly — but it is not a deregulation or an approval. The compound remains research-only, with no human clinical trial data and no drug approval in either the U.S. or Canada.
For researchers and institutions working in the peptide space, the most important takeaways are: source from verified suppliers with rigorous CoA documentation, stay current on regulatory updates as the landscape continues to shift, and apply appropriate research-only framing to all use cases.
WebberScience supplies research-grade BPC-157 with full third-party testing documentation for licensed Canadian research institutions. If you have questions about sourcing, specifications, or regulatory compliance for your research program, contact our team.
This article is for educational and informational purposes only. BPC-157 is a research compound not approved for human use by the FDA, Health Canada, or any other regulatory body. This content does not constitute medical advice.